SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001615774-17-006131
Filing Date
2017-11-01
Accepted
2017-11-01 16:44:45
Documents
1
Group Members
VIVO VENTURES FUND VI, L.P.VIVO VENTURES VI AFFILIATES FUND, L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A s107971_13da.htm SC 13D/A 59440
  Complete submission text file 0001615774-17-006131.txt   61119
Mailing Address 350 CAMBRIDGE AVE SUITE 350 PALO ALTO CA 94306
Business Address 350 CAMBRIDGE AVE SUITE 350 PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Subject) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-87931 | Film No.: 171169522
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 505 HAMILTON AVENUE, SUITE 200 PALO ALTO CA 94301
Business Address 505 HAMILTON AVENUE, SUITE 200 PALO ALTO CA 94301 (650) 688-0818
Vivo Ventures VI, LLC (Filed by) CIK: 0001469547 (see all company filings)

IRS No.: 208829402 | State of Incorp.: CA | Fiscal Year End: 1231
Type: SC 13D/A